Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Kevin Maki PhD, CLS, FNLA, FTOS, FACN

Kevin C. Maki PhD, CLS, FNLA, FTOS, FACN

Adjunct Professor, Dean’s Eminent Scholar, Department of Applied Health Science, Indiana University School of Public Health-Bloomington, Bloomington, Indiana

Kevin C. Maki, PhD, is the Founder and Chief Scientist for Midwest Biomedical Research (Chicago, Illinois). He specializes in the design and conduct of clinical studies in human nutrition, metabolism, and chronic disease risk factor management. Dr. Maki is also Adjunct Professor and Dean’s Eminent Scholar in the Department of Applied Health Science at the Indiana University School of Public Health, Bloomington, Indiana. He is immediate Past-President of the National Lipid Association and Co-Editor-in-Chief of the Journal of Clinical Lipidology.

Dr. Maki has participated in more than 300 clinical trials and observational studies as an investigator, consultant, or statistician. He earned a PhD in Epidemiology from the University of Illinois at Chicago’s School of Public Health, and an MS in Preventive and Rehabilitative Cardiovascular Health from Benedictine University.

Disclosures

Dr. Maki’s relevant disclosures include:

  • Novo Nordisk:  Research Grant Funding
  • Eli Lilly & Co:  Research Grant Funding, Advisory/Consulting Fees
  • Medifast:  Research Grant Funding, Advisory/Consulting Fees
  • General Mills:  Research Grant Funding